Eagle Pharmaceuticals | Sustainability Performance
Develops injectable and specialty pharmaceutical products.
2007
United States
51 - 200 employees
Pharmaceuticals
$100M - 500M in revenue
$25M - 100M in profitability
Sustainability Ranking & Industry Benchmark
#11486
Overall#2578
in United States#270
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and exclusionsB-corp & CDPFinancial Data
Business performanceCapital & innovation
Market cap
Revenue
R&D intensity
Controversy level
- Eagle Pharmaceuticals faced FDA Form 483 observations and quality compliance scrutiny over injectable products, plus periodic generic drug pricing practices affecting hospital customers.
Market cap
Revenue
EBITDA
Operating margin
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
10.8%FY2022
R&D as % of revenue
R&D as % of revenue
Industry benchmark
Powered by illuminem
Return on invested capital
12.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Not available
57%
Independent Directors
4 out of 7 incl. management
Overall score
18
Environment
3
Social
22
Governance
30
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
CDP Scores
Climate Score
Not disclosed
Water Score
Not disclosed
A
A-
B
B-
C
C-
D
D-
